Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News

7小时前

Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.

ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.

The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1179996720"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179996720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179996720?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179996720","market":"nz","top_or_hot":-1,"title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","media":"Stock News","content":"<p><b>Antengene-B</b> (<b>06996</b>) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.<br><br>ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.<br><br>The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-25 07:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Antengene-B</b> (<b>06996</b>) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.<br><br>ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.<br><br>The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1179996720","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","pubTimestamp":1787612662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1191":"制药","06996":"德琪医药-B","BK1583":"高瓴概念"},"translate_title":"Antengene 的 ATG-201 I 期 ATTRACT 试验获得澳大利亚伦理委员会批准用于 B 细胞自身免疫性疾病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}